Semaglutide shows a great promise to treat serious liver diseases

Semaglutide, the active ingredient in OzemPIC and Wegov, is preparing to add it to the growing medical uses menu. In a large -scale clinical experience published today, the stent in the blood was found to be effective in treating a relatively common and liver disease.

Researchers in the United States and the United Kingdom led the third stage experience, funded by the drug maker, Novo Nordisk. Compared to the imaginary medicine, heavily improved the results of people with poor metabolism associated with lipoproteitis (MASH). The results will pave the way to become sylphide and similar medications to become the treatments of lines facing this chronic condition.

Hormone is the most severe forms of democratic liver disease associated with the MALD. both of them Premium By excessive accumulation of fat in the liver, which can lead to ultimately harmful inflammation and scarring, or cirrhosis. These cases were previously known as NASH and NAFLD, respectively.

Masld is the most common form of liver disease – which affects a quarter of adults in the United States – although it does not cause clear symptoms. Most people who suffer from Masld do not advance to mash, but the condition still affects up to 6.5 % of American adults. Nash’s cirrhosis can raise the risk of other severe complications, including Liver cancer (The most common form of primary liver cancer) and explicit liver failure.

MALD/Mash caused several factors, including genetics for a person, but both obesity and diabetes The main shareholders. About 75 % of people with weight gain and 90 % of people with severe obesity have MALD; And between a third to two -thirds with type 2 diabetes they have as well. Looking at this close relationship, scientists were hoping that the pillar and similar drugs that mimic the GLP-1 (already approved for treatment would fall Obesity and diabetesIt can be an effective treatment for Masld/Mash as well.

The Novo Nordisk experience included the third stage, called Essence, about 800 patients with Mash. Volunteers are randomly assigned to receive a poultryide (up to 2.4 milligrams, which is currently the highest approved dose for obesity treatment) or a fictitious drug over 72 weeks. Both groups also received lifestyle consulting.

By the end of the study, nearly two-thirds of the semaglutide witnessed a decision of fatty hepatitis (hepatitis accompanied by fat accumulation)-about twice the percentage of those who suffered from the same time while they were in the placebo. People in the drug also witnessed a greater improvement in cirrhosis (the accumulation of scar tissue) than those in the imaginary medicine, and have lost more weight (about 10 % on average). People have suffered from similar harmful effects on the poultry, as shown in previous experiments, which often included symptoms of the digestive system such as nausea, diarrhea and vomiting.

“I was working with GLP-1 treatments for sixteen years, and these results are very exciting,” said co-author of Philip Newose, director of the Rogel Williams Institute for Kings College Studies. statement From the university. “Although these results should be treated with caution, the analysis shows that blood depression can be an effective tool for this advanced liver disease.”

It is almost certain that the results of the experiment, published on Wednesday in the New England Medicine Journal, have obtained the approval of the drug to treat mash from the Food and Drug Administration. The expected approval represents the latest penetration of a condition that had only drug treatments available recently. A little more than a year ago, Food and Drug Administration consent The first such drug, Rezdifra of Madrigal Pharmaceuticals.

Rezdiffra is a little different in terms of how he dealt with mash. It targets a different future that more specifically prevents the accumulation of fat in the liver without causing weight loss. But this is likely to be positive, because it must provide doctors and patients more treatment options to choose from, especially when people do not respond well to one or another.

Other GLP-1 medications (including Medicines that simulate other hormones related to weightIt is tested for the mash. So, if things continue to be fine, these medications may soon take a revolution in the treatment of mash, just as they were already for obesity.